MXPA03011861A - Particulas para inhalacion que tienen rapidas propiedades de liberacion. - Google Patents

Particulas para inhalacion que tienen rapidas propiedades de liberacion.

Info

Publication number
MXPA03011861A
MXPA03011861A MXPA03011861A MXPA03011861A MXPA03011861A MX PA03011861 A MXPA03011861 A MX PA03011861A MX PA03011861 A MXPA03011861 A MX PA03011861A MX PA03011861 A MXPA03011861 A MX PA03011861A MX PA03011861 A MXPA03011861 A MX PA03011861A
Authority
MX
Mexico
Prior art keywords
particles
formulations
bioactive agent
inhalation
release properties
Prior art date
Application number
MXPA03011861A
Other languages
English (en)
Inventor
P Batycky Richard
Original Assignee
Advanced Inhalation Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Inhalation Res Inc filed Critical Advanced Inhalation Res Inc
Publication of MXPA03011861A publication Critical patent/MXPA03011861A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Charge And Discharge Circuits For Batteries Or The Like (AREA)
  • Electric Propulsion And Braking For Vehicles (AREA)

Abstract

La invencion se refiere de forma general a formulaciones que tienen particulas que comprenden fosfolipidos, agentes bioactivos y excipientes y a la liberacion pulmonar de los mismos. Se describen formulacioens de insulina inhalada en forma de polvo seco. Se describen formulaciones mejoradas que comprenden DPPC, insulina y citrato sodico, que son utiles en el tratamiento de la diabetes. Ademas, la invencion se refiere a un metodo para la liberacion pulmonar de un agente bioactivo que comprende administrar en el tracto respiratorio de un paciente en necesidad de tratamiento o disgnosis, una cantidad eficaz de particulas que comprende un agente bioactivo o cualquier combinacion de los mismos, donde la liberacion del agente en las particulas administradas se produce de una forma rapida.
MXPA03011861A 2001-06-22 2002-06-24 Particulas para inhalacion que tienen rapidas propiedades de liberacion. MXPA03011861A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/888,126 US20020141946A1 (en) 2000-12-29 2001-06-22 Particles for inhalation having rapid release properties
PCT/US2002/020280 WO2003000202A2 (en) 2001-06-22 2002-06-24 Particles for inhalation having rapid release properties

Publications (1)

Publication Number Publication Date
MXPA03011861A true MXPA03011861A (es) 2004-03-26

Family

ID=25392579

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03011861A MXPA03011861A (es) 2001-06-22 2002-06-24 Particulas para inhalacion que tienen rapidas propiedades de liberacion.

Country Status (10)

Country Link
US (3) US20020141946A1 (es)
EP (1) EP1404299A2 (es)
JP (1) JP4067047B2 (es)
CN (1) CN1518441A (es)
CA (1) CA2449439A1 (es)
IL (1) IL158987A0 (es)
MX (1) MXPA03011861A (es)
NZ (1) NZ530123A (es)
PL (1) PL367399A1 (es)
WO (1) WO2003000202A2 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU2002333644A1 (en) * 2001-09-17 2003-04-01 Glaxo Group Limited Dry powder medicament formulations
CA2464656C (en) 2001-11-01 2013-07-16 Nektar Therapeutics Spray drying methods and compositions thereof
EP1894591B1 (en) 2002-03-20 2013-06-26 MannKind Corporation Cartridge for an inhalation apparatus
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
KR20060015316A (ko) * 2003-05-28 2006-02-16 넥타르 테라퓨틱스 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
WO2005032483A2 (en) * 2003-10-01 2005-04-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
WO2005034915A2 (en) * 2003-10-03 2005-04-21 Alza Corporation Screening method for evaluation of bilayer-drug interaction in liposomal compositions
US20050191360A1 (en) * 2004-02-10 2005-09-01 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
HUE028623T2 (en) 2005-09-14 2016-12-28 Mannkind Corp Active substance formulation method based on increasing the affinity of the active ingredient for binding to the surface of crystalline microparticles
US20070123449A1 (en) * 2005-11-01 2007-05-31 Advanced Inhalation Research, Inc. High load particles for inhalation having rapid release properties
US20070172430A1 (en) * 2006-01-20 2007-07-26 Nastech Pharmaceutical Company Inc. Dry powder compositions for rna influenza therapeutics
IN2015DN00888A (es) 2006-02-22 2015-07-10 Mannkind Corp
ES2570400T3 (es) 2008-06-13 2016-05-18 Mannkind Corp Un inhalador de polvo seco y un sistema para el suministro de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
CN104707130A (zh) * 2008-08-15 2015-06-17 阿索尔达治疗公司 在cns神经性损伤后非-急性期间处理的组合物及方法
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
MX354829B (es) 2009-03-26 2018-03-22 Pulmatrix Operating Co Inc Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares.
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
AU2010253776B2 (en) 2009-05-29 2015-01-22 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
US8485285B2 (en) * 2011-03-22 2013-07-16 Max Ferrigni Mobile product retail system and methods thereof
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
SE538214C2 (sv) * 2011-06-17 2016-04-05 Int Truck Intellectual Prop Co Övervakande styrsystem för hybrid-elektriska drivlinor
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
CN104487075A (zh) * 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
US8988037B1 (en) * 2012-04-06 2015-03-24 The United States Of America As Represented By The Secretary Of The Navy Solar panel storage and deployment system
WO2014012069A2 (en) 2012-07-12 2014-01-16 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
WO2014144894A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
DE102015004119A1 (de) * 2015-03-31 2016-10-06 Audi Ag Kraftfahrzeug mit einem elektrischen Energiespeicher und zwei Ladeschnittstellen, Ladesystem sowie Verfahren
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CN108348459A (zh) * 2015-09-09 2018-07-31 诺华股份有限公司 靶向递送喷雾干燥制剂到肺
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
US10516189B2 (en) * 2016-11-15 2019-12-24 Ford Global Technologies, Llc High voltage bus contactor fault detection
CN110662551B (zh) 2017-06-01 2023-07-18 伊莱利利公司 速效胰岛素组合物
MX2020006633A (es) * 2017-12-21 2021-01-15 Civitas Therapeutics Inc Formulaciones de surfactantes para inhalacion.
DE102021201828A1 (de) 2021-02-26 2022-09-01 Siemens Mobility GmbH Energieversorgungsanordnung und Verfahren, insbesondere für die Energieversorgung elektrisch betriebener Fahrzeuge, beispielsweise Schienenfahrzeuge sowie elektrisch betriebenes Fahrzeug, insbesondere Schienenfahrzeug

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2470296A (en) * 1948-04-30 1949-05-17 Abbott Lab Inhalator
US2992645A (en) * 1958-05-06 1961-07-18 Benger Lab Ltd Disperser for powders
US3957965A (en) * 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4089800A (en) * 1975-04-04 1978-05-16 Ppg Industries, Inc. Method of preparing microcapsules
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4743545A (en) * 1984-08-09 1988-05-10 Torobin Leonard B Hollow porous microspheres containing biocatalyst
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
CY1492A (en) * 1981-07-08 1990-02-16 Draco Ab Powder inhalator
EP0072046B1 (en) * 1981-07-24 1986-01-15 FISONS plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
DE3141641A1 (de) * 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
US4592436A (en) * 1982-08-19 1986-06-03 Tomei Edmardo J Solar powered vehicle
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4865789A (en) * 1983-11-14 1989-09-12 Akzo Nv Method for making porous structures
EP0163696B1 (en) * 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
US4679555A (en) * 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
JPS6150912A (ja) * 1984-08-16 1986-03-13 Shionogi & Co Ltd リポソ−ム製剤の製造法
AU587472B2 (en) * 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
US5340587A (en) * 1985-05-22 1994-08-23 Liposome Technology, Inc. Liposome/bronchodilator method & System
EP0248051A1 (en) * 1985-11-29 1987-12-09 FISONS plc Pharmaceutical composition including sodium cromoglycate
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
JP2765700B2 (ja) * 1986-08-11 1998-06-18 イノベータ・バイオメド・リミテツド マイクロカプセルを含有する医薬調合物
DE3637926C1 (de) * 1986-11-05 1987-11-26 Schering Ag Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US4963297A (en) * 1987-12-22 1990-10-16 The Liposome Company, Inc. Spontaneous vesticulation of multilamellar liposomes
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US4855144A (en) * 1987-10-23 1989-08-08 Advanced Polymer Systems Synthetic melanin aggregates
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4917119A (en) * 1988-11-30 1990-04-17 R. J. Reynolds Tobacco Company Drug delivery article
IT1228459B (it) * 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
WO1990013361A1 (en) * 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
IT1237118B (it) * 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
SE9002017D0 (sv) * 1990-06-06 1990-06-06 Kabivitrum Ab Process for manufacture of matrices
US5614216A (en) * 1990-10-17 1997-03-25 The Liposome Company, Inc. Synthetic lung surfactant
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5327883A (en) * 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
EP0679088B1 (en) * 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
US5698721A (en) * 1992-12-17 1997-12-16 Megabios Corporation Catonic amphiphiles
US5603945A (en) * 1993-02-19 1997-02-18 Takeda Chemical Industries, Ltd. Therapeutic/prophylactic agents and method of treating for urinary calculosis in pets
SE9301220D0 (sv) * 1993-04-14 1993-04-14 Kabi Pharmacia Ab Manufacturing matrices
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
DK0721331T3 (da) * 1993-10-01 2002-02-11 Astrazeneca Ab Fremgangsmåde
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
DK0748213T3 (da) * 1994-03-07 2004-08-02 Nektar Therapeutics Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin
CA2190502A1 (en) * 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
GB9413605D0 (en) * 1994-07-06 1994-08-24 American Colloid Co Method of increasing the size and absorption under load of super-absorbent fine particles by impregnation with an aqueous acrylic monomer solution
US5486569A (en) * 1994-09-28 1996-01-23 American Colloid Company Method of increasing the size and/or absorption under load of superabsorbent polymers by surface cross-linking and subsequent agglomeration of undersized particcles
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
AR002009A1 (es) * 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
ATE287703T1 (de) * 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5637980A (en) * 1995-05-08 1997-06-10 Wu; Jimmy Battery charging/discharging switching control protective circuit
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6103270A (en) * 1996-06-07 2000-08-15 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
AU6014098A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JP2000510434A (ja) * 1997-04-10 2000-08-15 ニューコン システムズ、インコーポレイション 厚壁セラミック製品の製造方法および装置
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
AU2484399A (en) * 1998-01-30 1999-08-16 Scios Inc. Controlled release delivery of peptide or protein
IL138687A0 (en) * 1998-04-08 2001-10-31 Lilly Co Eli Pulmonary and nasal delivery of raloxifene
US5986429A (en) * 1998-06-29 1999-11-16 Mula, Jr.; John Battery charging system for electric vehicles
US6586668B2 (en) * 1999-02-05 2003-07-01 Powerlight Corporation Electric vehicle with photovoltaic roof assembly
DE19937221C1 (de) * 1999-08-06 2000-09-07 Webasto Dachsysteme Gmbh Solar-Fahrzeugdach
US6227601B1 (en) * 2000-03-20 2001-05-08 Lafrance Joseph E. Motor driven sunshield
US6735645B1 (en) * 2001-09-04 2004-05-11 Lsi Logic Corporation System and method to eliminate race conditions in input/output operations for high bandwidth architectures
US6617822B1 (en) * 2001-09-12 2003-09-09 Bellsouth Intellectual Property Corporation System and method to maintain charge of vehicle battery using light energy
US20040201244A1 (en) * 2002-12-31 2004-10-14 Leon Neuer Automobile sunshade
US7140662B1 (en) * 2003-10-06 2006-11-28 Wilkinson Kari L Retractable sunshade
US7718923B1 (en) * 2007-02-09 2010-05-18 Hansen Scott P Defrosting windshield sunshade panel

Also Published As

Publication number Publication date
CA2449439A1 (en) 2003-01-03
NZ530123A (en) 2007-01-26
WO2003000202A2 (en) 2003-01-03
JP4067047B2 (ja) 2008-03-26
IL158987A0 (en) 2004-05-12
US20080227690A1 (en) 2008-09-18
PL367399A1 (en) 2005-02-21
JP2005500309A (ja) 2005-01-06
US20100026235A1 (en) 2010-02-04
US20020141946A1 (en) 2002-10-03
WO2003000202A3 (en) 2003-08-14
EP1404299A2 (en) 2004-04-07
CN1518441A (zh) 2004-08-04

Similar Documents

Publication Publication Date Title
MXPA03011861A (es) Particulas para inhalacion que tienen rapidas propiedades de liberacion.
US6616914B2 (en) Method for pulmonary and oral delivery of pharmaceuticals
WO2002053190A3 (en) Particles for inhalation having sustained release properties
US20080066739A1 (en) Methods and systems of delivering medication via inhalation
WO2002078675A3 (en) Particles for inhalation having sustained release properties
TNSN06277A1 (en) Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
EP1938814A4 (en) PHARMACEUTICAL PRODUCT FOR PROTECTING MOTOR NERVE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS
CA2421974A1 (en) Pulmonary delivery in treating disorders of the central nervous system
CA2478980A1 (en) Pulmonary delivery for levodopa
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
JP2007520506A5 (es)
HUP0300499A2 (en) Pharmaceutical formulations for dry powder inhalers
CA2550841A1 (en) Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
WO2005089448A3 (en) Administration of cisplatin by inhalation
JPH10508602A (ja) 肺の薬剤デリバリーを促進するための液体フルオロカーボンの使用
MXPA05009629A (es) Composiciones que contienen trospio.
Gryn et al. The toxicity of daily inhaled amphotericin B
KR20230111206A (ko) 혈관 질환 치료용 조성물, 혈관 질환 예방용 조성물, 고혈압 치료용 조성물 및 고혈압 예방용 조성물
HK1078795A1 (en) Powder formulations suitable for inhalation
TW200602054A (en) Use of compounds in a dry powder inhaler
JP2016528958A (ja) 経口薬物送達装置、及び、経口薬物送達装置の使用方法
WO2005077338A8 (en) Particles for inhalation rapid release properties
RU2010120806A (ru) Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
WO2007053729A3 (en) High load particles for inhalation having rapid release properties
KR101516057B1 (ko) 폐질환 치료용 흡입 제형 및 이의 제조방법

Legal Events

Date Code Title Description
FA Abandonment or withdrawal